In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Zosano Pharma (ZSAN – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $0.56, close to its 52-week low of $0.41.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of -2.0% and a 42.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.
Currently, the analyst consensus on Zosano Pharma is a Moderate Buy with an average price target of $2.00.
Based on Zosano Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.94 million. In comparison, last year the company had a GAAP net loss of $10.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zosano Pharma Corp. is a clinical stage pharmaceutical company, which engages in the provision of systemic administration of therapeutics to patients. It offers Qtrypta, a drug used orally and nasally to effectively and safely treat acute migraine. The company was founded in January 2012 and is headquartered in Fremont, CA.